Remifentanil
- Generic Name
- Remifentanil
- Brand Names
- Ultiva
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5
- CAS Number
- 132875-61-7
- Unique Ingredient Identifier
- P10582JYYK
- Background
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
- Indication
For use during the induction and maintenance of general anesthesia.
- Associated Conditions
- -
- Associated Therapies
- Immediate postoperative analgesia therapy, Induction and Maintenance of General Anesthesia, Monitored anesthesia care sedation
PRD-guided Analgesia During FESS for Intraoperative Blood Loss
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 120
- Registration Number
- NCT03417206
SPI-guided Analgesia During FESS for Intraoperative Blood Loss
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 120
- Registration Number
- NCT03417180
- Locations
- 🇵🇱
Medical University of Silesia, Sosnowiec, Silesia, Poland
Sedation Strategies for Therapeutic Bronchoscopy
- Conditions
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03406546
- Locations
- 🇨🇳
Faculty of Anesthesiology, Changhai Hospital, Shanghai, Shanghai, China
Sedation Strategies for Diagnostic Bronchoscopy
- Conditions
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT03406533
- Locations
- 🇨🇳
Faculty of Anesthesiology, Changhai Hospital, Shanghai, Shanghai, China
Controlled Sedation for Cataract Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Fundación Universitaria de Ciencias de la Salud
- Target Recruit Count
- 98
- Registration Number
- NCT03401606
Remifentanil Versus Dexmedetomidine for Post-Cardiac Surgery Patients With Noninvasive Ventilation Intolerance
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03395886
- Locations
- 🇨🇳
Zhongshan hospital, Fudan university, Shanghai, Shanghai, China
SPI-guided vs PRD-guided Analgesia During FESS for Intraoperative Blood Loss
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 105
- Registration Number
- NCT03389763
- Locations
- 🇵🇱
Medical University of Silesia, Sosnowiec, Silesia, Poland
Remifentanil for Preventing Propofol Injection Pain in Elderly Patients
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 52
- Registration Number
- NCT03330782
- Locations
- 🇰🇷
Jong Yeop Kim, Suwon, Gyeonggi-do, Korea, Republic of
Postoperative and Opioid Free Anesthesia
- Conditions
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 316
- Registration Number
- NCT03316339
- Locations
- 🇫🇷
Beaujon Hospital, Clichy, France
🇫🇷Nimes University Hospital, Nîmes, France
🇫🇷Saint-Brieuc Hospital, Saint-Brieuc, France
Deep Brain Stimulation (DBS) Sedation
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 20
- Registration Number
- NCT03283150
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.